↓ Skip to main content

Peanut immunotherapy

Overview of attention for article published in Clinical and Translational Allergy, September 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (85th percentile)

Mentioned by

twitter
15 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
43 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Peanut immunotherapy
Published in
Clinical and Translational Allergy, September 2014
DOI 10.1186/2045-7022-4-30
Pubmed ID
Authors

Katherine Anagnostou, Andrew Clark

Abstract

Peanut allergy is common and can be a cause of severe, life-threatening reactions. It is rarely outgrown like other food allergies, such as egg and milk. Peanut allergy has a significant effect on the quality of life of sufferers and their families, due to dietary and social restrictions, but mainly stemming from fear of accidental peanut ingestion. The current management consists of strict avoidance, education and provision of emergency medication, but a disease- modifying therapy is needed for peanut allergy. Recent developments involve the use of immunotherapy, which has shown promise as an active form of treatment. Various routes of administration are being investigated, including subcutaneous, oral, sublingual and epicutaneous routes. Other forms of treatment, such as the use of vaccines and anti-IgE molecules, are also under investigation. So far, results from immunotherapy studies have shown good efficacy in achieving desensitisation to peanut with a good safety profile. However, the issue of long-term tolerance has not been fully addressed yet and larger, phase III studies are required to further investigate safety and efficacy. An assessment of cost/benefit ratio is also required prior to implementing this form of treatment. The use of immunotherapy for peanut allergy is not currently recommended for routine clinical use and should not be attempted outside specialist allergy units.

Twitter Demographics

The data shown below were collected from the profiles of 15 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 43 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 19%
Student > Bachelor 6 14%
Other 6 14%
Researcher 5 12%
Student > Master 3 7%
Other 7 16%
Unknown 8 19%
Readers by discipline Count As %
Medicine and Dentistry 9 21%
Agricultural and Biological Sciences 7 16%
Biochemistry, Genetics and Molecular Biology 5 12%
Pharmacology, Toxicology and Pharmaceutical Science 4 9%
Immunology and Microbiology 4 9%
Other 5 12%
Unknown 9 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 November 2014.
All research outputs
#1,703,425
of 12,627,283 outputs
Outputs from Clinical and Translational Allergy
#131
of 383 outputs
Outputs of similar age
#30,294
of 210,810 outputs
Outputs of similar age from Clinical and Translational Allergy
#1
of 1 outputs
Altmetric has tracked 12,627,283 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 383 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 210,810 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them